NeuroDerm is presently developing a comprehensive portfolio of product candidates that are geared to resolve specific deficiencies in current treatment methodologies for the growing population of patients suffering from moderate to severe Parkinson’s disease. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). LD/CD increases dopamine concentrations in the brain, improves nerve conduction and alleviates movement disorders related to Parkinson’s disease. Based on this proprietary reformulation technology, NeuroDerm is developing a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream.
The LD/CD line of product candidates includes:
• ND0612L: for moderate Parkinson’s disease patients
• ND0612H: for severe Parkinson’s disease patients
In addition to the LD/CD line of product candidates, NeuroDerm is also developing a novel formulation of continuous apomorphine therapy. Continuous apomorphine therapy is aimed at Parkinson’s disease patients who do not respond well or cannot be treated with LD/CD. The current marketed apomorphine product suffers from detrimental side effects that prevent its more widespread use. ND0701 is NeuroDerm’s next-generation alternative to the currently available continuous apomorphine therapy.
We are also developing ND0801, a product candidate for patients suffering from cognitive disorders associated with central nervous system diseases. These diseases include Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer’s disease, Parkinson’s disease and schizophrenia. This line of products will be based on a combination of reformulated approved drugs and will allow for continuous administration via transdermal patches.